Skip to main content

Who’s afraid of Ozempic? From restaurants to package makers, companies work to calm investors’ GLP-1 jitters.

With Eli Lilly’s Zepbound set to enter the fray, companies are flooded with weight-loss drug questions
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.